FDA clears ProTom's Radiance proton therapy system

The U.S. Food and Drug Administration (FDA) has cleared proton therapy developer...Read more on AuntMinnie.comRelated Reading: ProTom files for bankruptcy protection ProTom begins installing synchrotron Proton therapy experts look back and to the future ProTom, MIT test accelerator
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

We thank the authors for bringing to our attention the previously reported association between significant genitourinary (GU) toxicity and absolute bladder volume exposed to 30-40 Gy during image guided proton therapy [1]. We had focused primarily on trials and data related to photon dosimetry. This information actually lends credence to the validity of our dosimetric observation that medium dose levels may be important determinant for symptomatic GU toxicity. We await the corresponding data from PIVOTAL and RTOG 0924 trials with interest.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Letter to the Editor Source Type: research
The accuracy of analytical dose calculations (ADC) and dose uncertainties resulting from anatomical changes are both limiting factors in proton therapy. For the latter, rapid plan adaption is necessary, whereas for the former, Monte Carlo (MC) approaches are instead being increasingly recommended. These however are inherently slower than analytical approaches, potentially limiting the ability to rapidly adapt plans. Here, we compare the clinical relevance of uncertainties resulting from both.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Publication date: Available online 2 April 2020Source: Radiation Physics and ChemistryAuthor(s): Shifeng Sun, Yang Liu, Xiaoping Ouyang
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
We report the safety data from the first multicenter phase I trial investigating the use of hypofractionated proton therapy with concurrent chemotherapy for patients with stage II or III non-small cell lung cancer (NSCLC).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
ConclusionsThe RAH has provided an important service to demonstrate the dosimetric difference between PBT and photon therapy for Australian patients, an important step in supporting the funding of patients for treatment overseas.
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Radiation Oncology —Original Article Source Type: research
We present a case of a 47-year-old woman with a history of right pleural mesothelioma status post partial pleurectomy, decortication, and intraoperative hyperthermic chemotherapy, followed by adjuvant proton radiation therapy. She also has a remote history of Hodgkin lymphoma treated with systemic chemotherapy and radiation therapy to the mediastinum. Three months post proton therapy, she presented with a progressive chronic cough and thick sputum production with spontaneous bronchial casts expectoration in the form of the bronchial tree (Figure).
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Medical image Source Type: research
eau S Abstract Computed tomography (CT) in the treatment position is currently indispensable for planning radiation therapy. Other imaging modalities, such as magnetic resonance imaging (MRI) and positron emission-tomography (PET), can be used to improve the definition of the tumour and/or healthy tissue but also to provide functional data of the target volume. Accurate image registration is essential for treatment planning, so MRI and PET scans should be registered at the planning CT scan. Hybrid PET/MRI scans with a hard plane can be used but pose the problem of the absence of CT scans. Finally, techniques for m...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
;l G, Valable S Abstract Imaging is critical to each step of precision radiation therapy, i.e. planning, setup, delivery and assessment of response. Hadrontherapy can be considered to deliver more precise dose distribution that may better spare normal tissues from intermediate low doses of radiation. In addition, hadrontherapy using high linear energy transfer ions may also be used for dose escalation on biological target volumes defined by functional imaging. However, the physical characteristics of hadrontherapy also make it more demanding in terms of imaging accuracy and image-based dose calculation. Some of th...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
This study proposes a PG-PET system that combines the advantages of these two methods and presents detector geometry and background reduction techniques optimized for the PG-PET system. The characteristics of the secondary radiations emitted by a water phantom by interaction with a 150 MeV proton beam were analysed using Geant4.10.00, and the 2-D PG distributions were obtained and assessed for different detector geometries. In addition, the energy window (EW), depth-of-interaction (DOI), and time-of-flight (TOF) techniques are proposed as the background reduction techniques. To evaluate the performance of the PG-PET system...
Source: Physics in Medicine and Biology - Category: Physics Authors: Tags: Phys Med Biol Source Type: research
PMID: 32245604 [PubMed - as supplied by publisher]
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
More News: Food and Drug Administration (FDA) | Proton Therapy | Radiology